Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenberg DW, Giardina C, Tanaka T. Mouse models for the study of colon carcinogenesis. Carcinogenesis. 2009;30(2):183–96.

Article  CAS  PubMed  Google Scholar 

Jussila A, Virta LJ, Pukkala E, Färkkilä MA. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol. 2013;48(12):1405–13.

Article  PubMed  Google Scholar 

Kappelman MD, Farkas DK, Long MD, Erichsen R, Sandler RS, Sørensen HT, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12(2):265-73.e1.

Article  PubMed  Google Scholar 

Mosher CA, Brown GR, Weideman RA, Crook TW, Cipher DJ, Spechler SJ, et al. Incidence of colorectal cancer and extracolonic cancers in veteran patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(3):617–23.

Article  PubMed  Google Scholar 

Burns JA, Weiner AB, Catalona WJ, Li EV, Schaeffer EM, Hanauer SB, et al. Inflammatory bowel disease and the risk of prostate cancer. Eur Urol. 2019;75(5):846–52.

Article  PubMed  Google Scholar 

Carli E, Caviglia GP, Pellicano R, Fagoonee S, Rizza S, Astegiano MS, et al. Incidence of prostate cancer in inflammatory bowel disease: a meta-analysis. Medicina (Kaunas). 2020;56(6):285.

Article  PubMed  Google Scholar 

Ge Y, Shi Q, Yao W, Cheng Y, Ma G. The association between inflammatory bowel disease and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis. 2020;23(1):53–8.

Article  PubMed  Google Scholar 

Meyers TJ, Weiner AB, Graff RE, Desai AS, Cooley LF, Catalona WJ, et al. Association between inflammatory bowel disease and prostate cancer: a large-scale, prospective, population-based study. Int J Cancer. 2020;147(10):2735–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He MM, Lo CH, Wang K, Polychronidis G, Wang L, Zhong R, et al. Immune-mediated diseases associated with cancer risks. JAMA Oncol. 2022;8(2):209–19.

Article  PubMed  Google Scholar 

Jung G, Song B, Kim JK, Kim H, Lee J, Hong SK. The association between inflammatory bowel disease and risk of prostate cancer: a population-based retrospective study based on Korean National Health Insurance Service database. Prostate Int. 2024. https://doi.org/10.1016/j.prnil.2024.05.001.

Article  PubMed  Google Scholar 

Wilson JC, Furlano RI, Jick SS, Meier CR. A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. J Gastroenterol. 2016;51(11):1050–62.

Article  CAS  PubMed  Google Scholar 

Na JE, Kim TJ, Lee YC, Kim JE, Kim ER, Hong SN, et al. Risk of prostate cancer in patients with inflammatory bowel disease: a nationwide cohort study in South Korea. Therap Adv Gastroenterol. 2022;21(15):17562848221137430.

Article  Google Scholar 

Ko SH, Baeg MK, Bae WJ, Kim P, Choi MG. Prostate cancer patients may have an increased risk of coexisting advanced colorectal neoplasms. Onco Targets Ther. 2016;9(9):5611–7.

PubMed  PubMed Central  Google Scholar 

Desautels D, Czaykowski P, Nugent Z, Demers AA, Mahmud SM, Singh H. Risk of colorectal cancer after the diagnosis of prostate cancer: a population-based study. Cancer. 2016;122(8):1254–60.

Article  PubMed  Google Scholar 

Beebe-Dimmer JL, Yee C, Paskett E, Schwartz AG, Lane D, Palmer NRA, et al. Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women’s health initiative. BMC Cancer. 2017;17(1):848.

Article  PubMed  PubMed Central  Google Scholar 

Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, Nishio K, et al. Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer. Carcinogenesis. 2014;35(9):2142–53.

Article  PubMed  PubMed Central  Google Scholar 

De Velasco MA, Kura Y, Yoshikawa K, Nishio K, Davies BR, Uemura H. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer. Oncotarget. 2016;7(13):15959–76.

Article  PubMed  PubMed Central  Google Scholar 

De Velasco MA, Kura Y, Sakai K, Hatanaka Y, Davies BR, Campbell H, et al. Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy. JCI Insight. 2019;4(17):e122688.

Article  PubMed  PubMed Central  Google Scholar 

Sakai K, De Velasco MA, Kura Y, Nishio K. Transcriptome profiling and metagenomic analysis help to elucidate interactions in an inflammation-associated cancer mouse model. Cancers (Basel). 2021;13(15):3683.

Article  CAS  PubMed  Google Scholar 

Clapper ML, Cooper HS, Chang WC. Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta Pharmacol Sin. 2007;28(9):1450–9.

Article  CAS  PubMed  Google Scholar 

Wargovich MJ, Chen CD, Harris C, Yang E, Velasco M. Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int J Cancer. 1995;60(4):515–9.

Article  CAS  PubMed  Google Scholar 

Krugliak Cleveland N, Torres J, Rubin DT. What does disease progression look like in ulcerative colitis, and how might it be prevented? Gastroenterology. 2022;162(5):1396–408.

Article  PubMed  Google Scholar 

Andersen SN, Rognum TO, Bakka A, Clausen OP. Ki-67: a useful marker for the evaluation of dysplasia in ulcerative colitis. Mol Pathol. 1998;51(6):327–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155(6):1985–92.

Article  PubMed  PubMed Central  Google Scholar 

Bénard A, Mittelstädt A, Klösch B, Glanz K, Müller J, Schoen J, et al. IL-3 orchestrates ulcerative colitis pathogenesis by controlling the development and the recruitment of splenic reservoir neutrophils. Cell Rep. 2023;42(6):112637.

Article  PubMed  Google Scholar 

Antuamwine BB, Bosnjakovic R, Hofmann-Vega F, Wang X, Theodosiou T, Iliopoulos I, et al. N1 versus N2 and PMN-MDSC: a critical appraisal of current concepts on tumor-associated neutrophils and new directions for human oncology. Immunol Rev. 2023;314(1):250–79.

Article  CAS  PubMed  Google Scholar 

Wang H, Tian T, Zhang J. Tumor-associated macrophages (TAMs) in colorectal cancer (CRC): from mechanism to therapy and prognosis. Int J Mol Sci. 2021;22(16):8470.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang C, Zhang J, Zhang Y, Song Z, Bian J, Yi H, et al. Identifying neutrophil-associated subtypes in ulcerative colitis and confirming neutrophils promote colitis-associated colorectal cancer. Front Immunol. 2023;10(14):1095098.

Article  Google Scholar 

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.

Article  CAS  PubMed  Google Scholar 

Hori M, Palmer M. Age-specific prostate cancer incidence rate in the world. Jpn J Clin Oncol. 2021;51(1):164–5.

Article  PubMed